<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767598</url>
  </required_header>
  <id_info>
    <org_study_id>07-109</org_study_id>
    <nct_id>NCT00767598</nct_id>
  </id_info>
  <brief_title>The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects</brief_title>
  <acronym>CYP3APDE5I</acronym>
  <official_title>The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors(PDE5I) in Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to evaluate the effect of CYP3A5*3 allele on the pharmacokinetics of sildenafil,
      udenafil, and vardenafil, the clinical trial using a single oral dose was conducted in Korean
      healthy male subjects whose genotype of CYP3A5 had been determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the different effect of the CYP3A5 genotype on the
      pharmacokinetics(PK) of sildenafil, udenafil, and vardenafil in healthy male subjects. Twenty
      one healthy male subjects with CYP3A5*1/*1, *1/*3, or *3/*3 were enrolled. An open-label
      3-way crossover study was performed with a week washout. A single oral dose of PDE5I (100 mg
      sildenafil; 200 mg udenafil; 20 mg vardenafil) was administered, respectively. After a single
      oral dose of phosphodiesterase type 5 inhibitor (PDE5I), plasma levels of the parent and the
      major metabolite were measured up to 24 or 48 h.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax, AUC</measure>
    <time_frame>upto 24hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Pharmacokinetics of Three PDE5Is</condition>
  <condition>Healthy Subjects</condition>
  <condition>Genetic Polymorphic CYP3A5</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vardenafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Udenafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phosphodiesterase type 5 inhibitor</intervention_name>
    <description>single oral administration of 20mg vardenafil</description>
    <arm_group_label>A</arm_group_label>
    <other_name>vardenafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phosphodiesterase type 5 inhibitor</intervention_name>
    <description>single oral administration of 100mg sildenafil</description>
    <arm_group_label>B</arm_group_label>
    <other_name>sildenafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phosphodiesterase type 5 inhibitor</intervention_name>
    <description>single oral administration of 200mg udenafil</description>
    <arm_group_label>C</arm_group_label>
    <other_name>udenafil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject whose CYP3A5 genotype was determined

        Exclusion Criteria:

          -  Subject whose CYP3A5 genotype was not determined
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Gook Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>October 6, 2008</last_update_submitted>
  <last_update_submitted_qc>October 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Department of Pharmacology and PharmacoGenomics Research Center</name_title>
    <organization>Inje University College of Medicine</organization>
  </responsible_party>
  <keyword>CYP3A5</keyword>
  <keyword>sildenafil</keyword>
  <keyword>udenafil</keyword>
  <keyword>vardenafil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
    <mesh_term>Udenafil</mesh_term>
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

